LifeMD, Inc. (LFMDP) Cash & Equivalents (2012 - 2025)

LifeMD (LFMDP) has 14 years of Cash & Equivalents data on file, last reported at $36.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 12.7% year-over-year to $36.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.8 million (up 12.7% YoY) and the FY2025 annual result came in at $36.8 million, up 12.7% from the prior year.
• Cash & Equivalents climbed to $36.8 million in Q4 2025, from $23.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $41.3 million in Q4 2021 to a low of $4.0 million in Q4 2022.
• A 5-year average of $23.9 million and a median of $25.1 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 3646.16% — and 2022, when it plunged 90.42%.
• Tracing LFMDP's Cash & Equivalents over 5 years: stood at $41.3 million in 2021, then sank by 90.42% to $4.0 million in 2022, then surged by 737.26% to $33.1 million in 2023, then declined by 1.49% to $32.7 million in 2024, then advanced by 12.7% to $36.8 million in 2025.
• The last three Cash & Equivalents figures came in at $36.8 million (Q4 2025), $23.8 million (Q3 2025), and $36.2 million (Q2 2025), per Business Quant data.